1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of CNS related diseases
申请人:Hoffmann-La Roche Inc.
公开号:US11021448B2
公开(公告)日:2021-06-01
The present invention provides compounds that are muscarinic M1 receptor positive allosteric modulators (PAM) and useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
本发明提供的化合物是毒蕈碱 M1 受体正性异位调节剂 (PAM),可用于治疗由毒蕈碱 M1 受体介导的疾病,如阿尔茨海默氏症、认知障碍、精神分裂症、疼痛或睡眠障碍;本发明还提供了这些化合物的制造方法、含有这些化合物的药物组合物及其作为治疗活性物质的用途。